Hematopathology — MCQs
On this page
A 55-year-old man complains of pain in his back, fatigue, and occasional confusion. He admits to polyuria and polydipsia. An X-ray examination reveals numerous lytic lesions in the lumbar vertebral bodies. Laboratory studies disclose hypoalbuminemia, mild anemia, and thrombocytopenia. A monoclonal IgG peak is demonstrated by serum electrophoresis. Urinalysis shows 4+ proteinuria. A bone marrow biopsy discloses foci of plasma cells, which account for 18% of all hematopoietic cells. What is the appropriate diagnosis?
In Chronic Lymphocytic Leukemia (CLL), which cell type predominates?
What does Von Willebrand factor deficiency cause?
Which CD marker is characteristic of hematopoietic stem cells?
Platelet count is decreased in all of the following conditions except:
The most important example of a compensated hemolytic anemia becoming decompensated occurs when:
In sickle cell disease, which of the following does not influence the degree of sickling of red cells?
Disseminated intravascular coagulation (DIC) is seen in:
Which of the following statements about blood transfusion are true?
All of the following are T cell lymphomas, EXCEPT:
Hematopathology Indian Medical PG Practice Questions and MCQs
Question 31: A 55-year-old man complains of pain in his back, fatigue, and occasional confusion. He admits to polyuria and polydipsia. An X-ray examination reveals numerous lytic lesions in the lumbar vertebral bodies. Laboratory studies disclose hypoalbuminemia, mild anemia, and thrombocytopenia. A monoclonal IgG peak is demonstrated by serum electrophoresis. Urinalysis shows 4+ proteinuria. A bone marrow biopsy discloses foci of plasma cells, which account for 18% of all hematopoietic cells. What is the appropriate diagnosis?
- A. Acute lymphoblastic leukemia
- B. Chronic lymphocytic leukemia
- C. Extramedullary plasmacytoma
- D. Multiple myeloma (Correct Answer)
Explanation: **Explanation:** The clinical presentation is a classic case of **Multiple Myeloma (MM)**, a neoplastic proliferation of plasma cells [1]. The diagnosis is confirmed by the presence of the **CRAB** criteria: * **C (Calcium elevation):** Suggested by confusion, polyuria, and polydipsia (symptoms of hypercalcemia) [3]. * **R (Renal insufficiency):** Indicated by 4+ proteinuria (Bence-Jones proteins) [4]. * **A (Anemia):** Present along with thrombocytopenia due to marrow infiltration [2]. * **B (Bone lesions):** X-ray shows characteristic "punched-out" lytic lesions in the vertebrae [2]. The laboratory findings of a **monoclonal IgG peak (M-spike)** on serum electrophoresis and **>10% plasma cells** in the bone marrow (18% in this case) are definitive diagnostic markers for MM [1], [5]. **Why incorrect options are wrong:** * **Acute Lymphoblastic Leukemia (ALL):** Typically presents in children with lymphoblasts in the marrow, not plasma cells or lytic bone lesions. * **Chronic Lymphocytic Leukemia (CLL):** Characterized by mature B-cell lymphocytosis and "smudge cells" on peripheral smear; it does not typically cause lytic bone lesions. * **Extramedullary Plasmacytoma:** This refers to a plasma cell tumor occurring outside the bone marrow (most commonly in the upper respiratory tract) without the systemic features or marrow involvement seen here. **High-Yield Pearls for NEET-PG:** * **Most common primary malignancy of bone** in adults. * **M-protein:** Most common is **IgG** (>50%), followed by IgA [5]. * **Peripheral Smear:** Shows **Rouleaux formation** due to increased serum proteins [4]. * **Urine:** Bence-Jones proteins (light chains) precipitate at 40-60°C and redissolve at 100°C. * **Diagnosis:** Bone marrow biopsy is the gold standard (shows "clock-face" nuclei and perinuclear clearing/hof). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 616-617. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 617-618. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 618-619. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 607-608. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 608-609.
Question 32: In Chronic Lymphocytic Leukemia (CLL), which cell type predominates?
- A. T cell
- B. B cell (Correct Answer)
- C. Lymphocyte
- D. Monocyte
Explanation: **Explanation:** **Chronic Lymphocytic Leukemia (CLL)** is a monoclonal proliferation of morphologically mature but immunologically incompetent lymphocytes [1]. **1. Why B cell is the correct answer:** CLL is fundamentally a **B-cell neoplasm**. In over 95% of cases, the malignant cells are mature B lymphocytes [1]. These cells express characteristic B-cell surface markers such as **CD19, CD20, and CD23**. A hallmark diagnostic feature is the co-expression of **CD5**, a marker normally found on T cells, which helps differentiate CLL from other B-cell lymphomas. These cells are arrested in the G0/G1 phase of the cell cycle, leading to progressive accumulation in the blood, bone marrow, and secondary lymphoid organs [1]. **2. Why other options are incorrect:** * **A. T cell:** While T-cell prolymphocytic leukemia exists, it is a distinct and much rarer entity. CLL is by definition a B-cell malignancy. * **C. Lymphocyte:** While technically true that these are lymphocytes, this option is too non-specific. NEET-PG questions require the most specific answer; identifying the lineage (B-cell) is the clinical standard. * **D. Monocyte:** Monocytes are myeloid lineage cells. Their proliferation is associated with conditions like Chronic Myelomonocytic Leukemia (CMML), not CLL. **3. High-Yield Clinical Pearls for NEET-PG:** * **Smudge Cells:** Fragile lymphocytes that burst during film preparation (characteristic finding). * **Immunophenotype:** CD5+, CD19+, CD20+ (weak), CD23+, and **Cyclin D1 negative** (to rule out Mantle Cell Lymphoma) [2]. * **Richter Transformation:** Progression of CLL into Diffuse Large B-Cell Lymphoma (DLBCL), seen in ~5-10% of patients. * **Hypogammaglobulinemia:** Common complication leading to increased susceptibility to bacterial infections. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 612-613. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 610-612.
Question 33: What does Von Willebrand factor deficiency cause?
- A. Platelet adhesion
- B. Factor VIII in plasma
- C. Defective platelet adhesion
- D. All of the above (Correct Answer)
Explanation: **Explanation:** Von Willebrand Factor (vWF) is a large multimeric glycoprotein that plays a dual role in hemostasis. Understanding its deficiency requires looking at its two primary functions: 1. **Platelet Adhesion:** vWF acts as a molecular bridge between the subendothelial collagen and the platelet surface receptor **GpIb-IX-V** [1]. In vWF deficiency, platelets cannot adhere to the site of vascular injury, leading to **defective platelet adhesion** (Option C) [1], [2]. This manifests clinically as a prolonged bleeding time and mucosal bleeding. 2. **Stabilization of Factor VIII:** In the circulation, vWF binds to and stabilizes **Factor VIII**, protecting it from rapid degradation by Protein C [2]. Therefore, a deficiency in vWF leads to a secondary decrease in the levels of **Factor VIII in plasma** (Option B) [2]. This explains why severe cases (Type 3 vWD) can mimic the clinical presentation of Hemophilia A (prolonged aPTT). **Why "All of the above" is correct:** The question asks what vWF deficiency "causes" or involves. It involves a defect in the physiological process of **platelet adhesion** (Option A/C) and directly impacts the levels of **Factor VIII** (Option B). In the context of multiple-choice questions, when a deficiency results in the impairment of a specific physiological mechanism (adhesion) and a reduction in a specific plasma factor (FVIII), all related parameters are affected. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common:** vWD is the most common inherited bleeding disorder. * **Inheritance:** Most types are Autosomal Dominant (unlike Hemophilia, which is X-linked). * **Diagnostic Test:** The **Ristocetin Cofactor Assay** is the gold standard (Ristocetin induces vWF-mediated platelet agglutination). * **Treatment:** **Desmopressin (DDAVP)** is used in Type 1 to release stored vWF from Weibel-Palade bodies in endothelial cells. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 668-670.
Question 34: Which CD marker is characteristic of hematopoietic stem cells?
- A. CD 34 (Correct Answer)
- B. CD 1
- C. CD19
- D. CD 21
Explanation: **Explanation:** **Correct Option: A (CD 34)** CD 34 is a transmembrane glycophosphoprotein expressed on **hematopoietic stem cells (HSCs)** and progenitor cells [1]. It is the gold-standard marker used in clinical practice to identify, quantify, and isolate stem cells for **bone marrow transplantation**. As these cells mature and differentiate into specific lineages, the expression of CD 34 is lost [1]. **Analysis of Incorrect Options:** * **CD 1:** This is a marker for **cortical thymocytes** and **Langerhans cells**. It is structurally similar to MHC Class I and is involved in presenting lipid antigens to T-cells. * **CD 19:** This is a pan-**B-cell marker**. It is expressed from the early stages of B-cell development (pro-B cell) until the terminal differentiation into plasma cells (where it is usually lost). * **CD 21:** Also known as Complement Receptor 2 (CR2), it is found on mature B-cells and **follicular dendritic cells**. It serves as the receptor for the **Epstein-Barr Virus (EBV)**. **High-Yield Clinical Pearls for NEET-PG:** * **Flow Cytometry:** In cases of Acute Leukemia, CD 34 positivity helps identify the "blast" nature of the cells, indicating an immature origin. * **Stem Cell Harvest:** For peripheral blood stem cell transplantation, G-CSF is given to mobilize CD 34+ cells from the marrow into the blood [2]. A minimum threshold (usually >2 x 10⁶ cells/kg) is required for a successful graft. * **Other HSC Markers:** While CD 34 is the primary marker, HSCs are also typically **CD 38 negative** and **HLA-DR negative** in their most primitive state. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Heart, pp. 588-589. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 585-586.
Question 35: Platelet count is decreased in all of the following conditions except:
- A. Henoch-Schonlein Purpura (Correct Answer)
- B. Idiopathic thrombocytopenic purpura
- C. Thrombotic thrombocytopenic purpura
- D. Systemic lupus erythematosus
Explanation: **Explanation:** The core concept tested here is the differentiation between **Vascular Purpura** and **Thrombocytopenic Purpura**. [2] **1. Why Henoch-Schönlein Purpura (HSP) is the correct answer:** HSP is an **IgA-mediated small-vessel vasculitis** (leukocytoclastic vasculitis). The purpuric rash occurs due to inflammation and increased permeability of the blood vessel walls, leading to the leakage of RBCs into the skin. Crucially, the **platelet count and coagulation profile remain normal**. It is characterized by the clinical tetrad of palpable purpura (usually on lower limbs), arthralgia, abdominal pain, and renal involvement (IgA nephropathy). **2. Analysis of Incorrect Options:** * **Idiopathic Thrombocytopenic Purpura (ITP):** This is an autoimmune condition where anti-platelet antibodies (usually IgG against GpIIb/IIIa) lead to premature destruction of platelets in the spleen, resulting in **isolated thrombocytopenia**. [1] * **Thrombotic Thrombocytopenic Purpura (TTP):** This is a microangiopathic hemolytic anemia (MAHA) caused by a deficiency of **ADAMTS13**. It leads to extensive microthrombi formation, which **consumes platelets**, causing severe thrombocytopenia. [4] * **Systemic Lupus Erythematosus (SLE):** Thrombocytopenia is a common hematological manifestation of SLE (Type II Hypersensitivity), where autoantibodies are directed against platelets, similar to the mechanism in ITP. [5] **High-Yield Clinical Pearls for NEET-PG:** * **Palpable Purpura + Normal Platelet Count** = Think Vasculitis (like HSP). * **Non-palpable Purpura + Low Platelet Count** = Think Thrombocytopenia (like ITP). [3] * **HSP Triad on Immunofluorescence:** IgA, C3, and fibrin deposition in the subendothelial region of small vessels. * **TTP Pentad:** Fever, Microangiopathic Hemolytic Anemia (Schistocytes), Thrombocytopenia, Neurological symptoms, and Renal failure. [4] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 666-667. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 619-620. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 620-621. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 667-668. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 665-666.
Question 36: The most important example of a compensated hemolytic anemia becoming decompensated occurs when:
- A. Infected with TB
- B. Infected with parvovirus B19 (Correct Answer)
- C. Liver disease
- D. Renal cell carcinoma
Explanation: ### Explanation **Why Parvovirus B19 is correct:** In patients with chronic hemolytic anemias (e.g., Hereditary Spherocytosis, Sickle Cell Anemia), the bone marrow is in a state of hyper-regeneration to compensate for the shortened lifespan of RBCs. **Parvovirus B19** specifically targets and destroys **erythroid progenitor cells** (proerythroblasts) by binding to the **P-antigen** on their surface [1]. In a healthy individual, this causes a mild, transient drop in RBC production. However, in a patient with compensated hemolysis, this sudden cessation of erythropoiesis leads to a rapid drop in hemoglobin levels, known as an **Aplastic Crisis** [1]. This represents a shift from a compensated state to a life-threatening decompensated state [1]. **Why the other options are incorrect:** * **A. Infected with TB:** While chronic infections like Tuberculosis can cause "Anemia of Chronic Disease" (due to hepcidin-mediated iron sequestration), they do not cause the acute, selective marrow failure characteristic of a decompensated hemolytic crisis. * **C. Liver disease:** Liver disease may lead to anemia via hypersplenism (sequestration) or target cell formation, but it is a chronic process rather than an acute trigger for decompensation. * **D. Renal cell carcinoma:** This is typically associated with **paraneoplastic erythrocytosis** (increased RBCs) due to ectopic Erythropoietin (EPO) production, the opposite of anemia. **High-Yield Clinical Pearls for NEET-PG:** * **Hallmark of Aplastic Crisis:** Sudden drop in Hemoglobin + **Reticulocytopenia** (low reticulocyte count), distinguishing it from a hyperhemolytic crisis [1]. * **Morphology:** Bone marrow biopsy in Parvovirus B19 infection shows characteristic **Giant Pronormoblasts** with viral inclusions. * **Fifth Disease:** In children, Parvovirus B19 causes *Erythema Infectiosum* (Slapped-cheek rash). * **Hydrops Fetalis:** Parvovirus B19 infection in pregnancy can lead to severe fetal anemia and heart failure. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 641-642.
Question 37: In sickle cell disease, which of the following does not influence the degree of sickling of red cells?
- A. Hereditary persistence of fetal hemoglobin
- B. Intracellular pH
- C. Intake of primaquine (Correct Answer)
- D. Co-existing a-thalassemia
Explanation: The degree of sickling in Sickle Cell Disease (SCD) is primarily determined by the concentration of Deoxy-HbS and the duration of time red cells spend in the microcirculation. [1] **Why Option C is Correct:** **Intake of Primaquine** does not influence sickling. Primaquine is an oxidizing agent that triggers hemolysis in **G6PD deficiency** by causing oxidative stress and Heinz body formation. [1] It has no direct effect on the polymerization of Hemoglobin S or the sickling process. **Why Other Options are Incorrect:** * **Hereditary Persistence of Fetal Hemoglobin (HPFH):** HbF (α2γ2) inhibits the polymerization of HbS because the γ-globin chain does not interact well with the βS chain. High levels of HbF are strongly protective and decrease the severity of sickling. [1] * **Intracellular pH:** A decrease in pH (acidosis) reduces the oxygen affinity of hemoglobin (Bohr effect). This increases the concentration of deoxygenated HbS, which promotes rapid polymerization and sickling. [1] * **Co-existing α-thalassemia:** This reduces the intracellular concentration of hemoglobin (MCHC). Since the rate of HbS polymerization is highly dependent on its concentration, a lower MCHC (due to α-thalassemia) significantly reduces sickling. [1] **NEET-PG High-Yield Pearls:** 1. **MCHC:** The most important factor determining sickling is the **Mean Corpuscular Hemoglobin Concentration**. [1] Dehydration increases MCHC and worsens sickling. 2. **Transit Time:** Factors that slow blood flow (e.g., inflammation, stasis) increase the time RBCs spend in the deoxygenated state, promoting sickling. [1] 3. **HbA2:** Unlike HbF, HbA2 has no significant inhibitory effect on HbS polymerization. 4. **Howell-Jolly Bodies:** These are seen on peripheral smears due to functional asplenia (autosplenectomy) in SCD patients. [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 642-646.
Question 38: Disseminated intravascular coagulation (DIC) is seen in:
- A. Acute promyelocytic leukemia (Correct Answer)
- B. Acute myelomonocytic leukemia
- C. Chronic myelogenous leukemia (CML)
- D. Autoimmune hemolytic anemia
Explanation: **Explanation:** **Acute Promyelocytic Leukemia (APL/AML-M3)** is the correct answer because it is classically associated with a severe, life-threatening coagulopathy, most commonly **Disseminated Intravascular Coagulation (DIC)** [4]. The underlying mechanism involves the presence of numerous **Auer rods** and primary granules within the neoplastic promyelocytes [1]. These cells release **Tissue Factor (TF)** and **Procoagulant substances** (Annexin II) into the circulation, which trigger the extrinsic coagulation pathway [2]. Additionally, the release of plasminogen activators leads to primary fibrinolysis. This "double hit" of systemic clotting and bleeding is a medical emergency often exacerbated by the initiation of chemotherapy (due to cell lysis). **Analysis of Incorrect Options:** * **B. Acute Myelomonocytic Leukemia (AML-M4):** While AML-M4 and M5 (Monocytic) are associated with extramedullary involvement (e.g., gingival hyperplasia), they do not characteristically present with DIC as a primary feature [1]. * **C. Chronic Myelogenous Leukemia (CML):** CML typically presents with massive splenomegaly and a hypercellular marrow. While it can progress to a "blast crisis," DIC is not a standard feature of the chronic or accelerated phases. * **D. Autoimmune Hemolytic Anemia (AIHA):** This is a type II hypersensitivity reaction involving autoantibodies against RBC antigens. It leads to hemolysis but does not trigger the systemic activation of the coagulation cascade seen in DIC [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Cytogenetics:** APL is defined by the **t(15;17)** translocation, involving the **PML-RARA** fusion gene [4]. * **Morphology:** Look for **"Faggot cells"** (cells containing bundles of Auer rods) on the peripheral smear [1]. * **Treatment:** The standard of care is **All-Trans Retinoic Acid (ATRA)** and Arsenic Trioxide, which promotes the differentiation of promyelocytes into mature neutrophils, rapidly resolving the DIC. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 621-622. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 671-672. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 151-152. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-621.
Question 39: Which of the following statements about blood transfusion are true?
- A. Antigen D determines Rh positivity.
- B. Febrile reaction is due to HLA antibodies.
- C. Anti-D is a naturally occurring antibody. (Correct Answer)
- D. Cryoprecipitate contains all coagulation factors.
Explanation: ### Explanation **Correct Answer: C. Anti-D is a naturally occurring antibody.** In the context of blood banking, "naturally occurring" antibodies (like Anti-A or Anti-B) are typically IgM and develop without prior exposure to foreign red cells [1]. However, **Anti-D is an immune antibody (IgG)**; it only develops after an Rh-negative individual is sensitized by Rh-positive blood (via transfusion or pregnancy) [1], [2]. *Note: There appears to be a discrepancy in the provided key. In standard medical pathology, Option C is technically **false**, and Option A is **true**. In the context of NEET-PG, always verify if the question asks for the "False" statement, as Anti-D is NOT naturally occurring.* #### Analysis of Other Options: * **A. Antigen D determines Rh positivity:** This is **True**. The Rh system consists of many antigens (C, c, E, e), but the **D antigen** is the most immunogenic [1]. Its presence on the RBC membrane defines an individual as Rh-positive [1], [2]. * **B. Febrile Non-Hemolytic Transfusion Reaction (FNHTR):** This is **True**. It is primarily caused by recipient antibodies directed against donor **HLA antigens** on leukocytes or cytokines released during storage. * **D. Cryoprecipitate:** This is **False**. Cryoprecipitate is a concentrated subset of plasma. It contains only **Factor VIII, Von Willebrand Factor (vWF), Fibrinogen, Factor XIII, and Fibronectin**. It does *not* contain all coagulation factors (Fresh Frozen Plasma is used for that). #### High-Yield Clinical Pearls for NEET-PG: 1. **Most common transfusion reaction:** Febrile Non-Hemolytic Transfusion Reaction (FNHTR). 2. **Most common cause of fatal transfusion reaction:** Clerical/Administrative error leading to ABO incompatibility [3]. 3. **Universal Donor:** O negative (RBCs); AB positive (Plasma). 4. **TRALI (Transfusion-Related Acute Lung Injury):** Caused by donor antibodies against recipient neutrophils/HLA; it is the leading cause of transfusion-related mortality. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 627-628. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 469-470. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 673-674.
Question 40: All of the following are T cell lymphomas, EXCEPT:
- A. Lymphoplasmacytic lymphoma (Correct Answer)
- B. Mycosis fungoides
- C. Anaplastic large cell lymphoma
- D. Aggressive NK cell leukemia
Explanation: **Explanation:** The correct answer is **A. Lymphoplasmacytic lymphoma (LPL)**. **1. Why Lymphoplasmacytic Lymphoma is the Correct Answer:** LPL is a **B-cell neoplasm** [1] characterized by a proliferation of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells. It is most commonly associated with **Waldenström Macroglobulinemia**, where there is a monoclonal IgM paraprotein (M-spike) in the blood. Because it originates from the B-cell lineage, it is not a T-cell lymphoma. **2. Analysis of Incorrect Options:** * **Mycosis Fungoides (B):** This is the most common type of **Cutaneous T-cell Lymphoma (CTCL)** [2]. It is characterized by the malignant proliferation of CD4+ helper T cells in the skin (Pautrier microabscesses) [3]. * **Anaplastic Large Cell Lymphoma (C):** This is a high-grade **T-cell lymphoma** characterized by large "hallmark cells" (horseshoe-shaped nuclei) [2] and is typically positive for **CD30**. It often involves the ALK gene translocation t(2;5) [4]. * **Aggressive NK cell leukemia (D):** This is a systemic neoplastic proliferation of **Natural Killer (NK) cells**, which are closely related to the T-cell lineage (often grouped under Mature T and NK-cell neoplasms in the WHO classification) [1]. It is strongly associated with the Epstein-Barr Virus (EBV). **3. High-Yield Clinical Pearls for NEET-PG:** * **LPL/Waldenström:** Look for "Hyperviscosity syndrome" (visual disturbances, neurological symptoms) and the absence of lytic bone lesions (unlike Multiple Myeloma). * **Genetics:** LPL is highly associated with the **MYD88 L265P mutation** (>90% of cases). * **CD Markers:** T-cell lymphomas typically express CD2, CD3, CD5, and CD7. LPL will express B-cell markers like CD19, CD20, and CD22. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 596-598. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 613-614. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 564-565. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 565-566.
Practice by Chapter
Anemias: Classification and Approach
Practice Questions
Hemolytic Anemias
Practice Questions
Myeloproliferative Neoplasms
Practice Questions
Myelodysplastic Syndromes
Practice Questions
Acute Leukemias
Practice Questions
Chronic Leukemias
Practice Questions
Lymphomas and Lymphoid Neoplasms
Practice Questions
Plasma Cell Disorders
Practice Questions
Bleeding Disorders
Practice Questions
Thrombotic Disorders
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free